10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells

Oncology Letters

Volumn 8, Issue 3, 2014, Pages 1355-1359

  Mu, Qitian ^a,b,c   Ma, Qiuling ^a,b   Lu, Shasha ^a,b   Zhang, Ting ^a,b   Yu, Mengxia ^a,b   Huang, Xin ^a,b   Chen, Jian ^a,b   Jin, Jie ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Key of Laboratory Hematopoietic Malignancies   (China)

^c NINGBO FIRST HOSPITAL   (China)

Author keywords

c Myc inhibitors; CCRF CEM; Cell death; Jurkat; T cell acute lymphoblastic leukemia; Valproic acid

Indexed keywords

10058 F4; CASPASE 3; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL DEATH; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84904245659     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2277     Document Type: Article

References (30)

1. Demarest RM, Ratti F and Capobianco AJ: It's T-ALL about Notch. Oncogene 27: 5082-5091, 2008.
2. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271, 2004.
3. Sarmento LM and Barata JT: Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev Anticancer Ther 11: 1403-1415, 2011.
4. Thompson BJ, Jankovic V, Gao J, et al: Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 205: 1395-1408, 2008.
5. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al: c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20: 2096-2109, 2006.
6. Malempati S, Tibbitts D, Cunningham M, et al: Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia 20: 1572-1581, 2006.
7. Shao N, Ma D, Wang J, Lu T, Guo Y and Ji C: Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells. Ann Hematol 92: 33-39, 2013.
8. Nie D, Huang K, Yin S, et al: Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 53: 2487-2495, 2012.
9. Kuendgen A, Knipp S, Fox F, et al: Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 84: 61-66, 2005.
10. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al: Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108: 1174-1182, 2006.
11. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H and Garcia-Manero G: Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29: 739-748, 2005.
12. Leiva M, Moretti S, Soilihi H, et al: Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26: 1630-1637, 2012.
13. Cheng YC, Lin H, Huang MJ, Chow JM, Lin S and Liu HE: Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 31: 1403-1411, 2007.
14. Kutuk O, Pedrech A, Harrison P and Basaga H: Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation. Apoptosis 10: 597-609, 2005.
15. Huang MJ, Cheng YC, Liu CR, Lin S and Liu HE: A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34: 1480-1489, 2006.
16. Holien T, Vatsveen TK, Hella H, et al: Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia 26: 1073-1080, 2012.
17. Masetti R, Serravalle S, Biagi C and Pession A: The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol 2011: 148046, 2011.
18. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
19. Fandy TE, Shankar S, Ross DD, Sausville E and Srivastava RK: Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7: 646-657, 2005.
20. Heider U, Kaiser M, Sterz J, et al: Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 76: 42-50, 2006.
21. Zhao ZN, Bai JX, Zhou Q, et al: TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One 7: e45133, 2012.
22. O'Neil J, Grim J, Strack P, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204: 1813-1824, 2007.
23. Kawagoe R, Kawagoe H and Sano K: Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and-independent apoptotic signaling pathways. Leuk Res 26: 495-502, 2002.
24. Xie C, Edwards H, Xu X, et al: Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 16: 5499-5510, 2010.
25. Jasek E, Lis GJ, Jasinska M, Jurkowska H and Litwin JA: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells. Anticancer Res 32: 2791-2799, 2012.
26. Wang AH, Wei L, Chen L, et al: Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 90: 917-931, 2011.
27. Schwartz C, Palissot V, Aouali N, et al: Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 30: 573-582, 2007.
28. Prochownik EV and Vogt PK: Therapeutic Targeting of Myc. Genes Cancer 1: 650-659, 2010.
29. Ott CJ, Kopp N, Bird L, et al: BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843-2852, 2012.
30. Filippakopoulos P, Qi J, Picaud S, et al: Selective inhibition of BET bromodomains. Nature 468: 1067-1073, 2010.